In vitro–in vivo correlation: Importance of dissolution in IVIVC

Dissolution Technologies

Volumn 14, Issue 1, 2007, Pages 15-19

  Cardot, J M ^a   Beyssac, E ^a   Alric, M ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CORRELATION ANALYSIS; DIGESTIVE SYSTEM; DISSOLUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; FOOD AND DRUG ADMINISTRATION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLUID; MINIMUM PLASMA CONCENTRATION; PHARMACEUTICAL CARE; QUALITY CONTROL;

EID: 44949089872     PISSN: 1521298X     EISSN: None     Source Type: Journal    
DOI: 10.14227/DT140107P15     Document Type: Article

References (23)

1. International Conference on Harmonisation Steering Committee. Pharmaceutical Development Q8;Draft Consensus Guideline, Released for Consultation at Step 2 of the ICH Process; International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use,18 November 2004.
2. Extended Release Oral Dosage Forms:Development, Evaluation, and Application of In Vitro/In Vivo Correlations; Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration,Center for Drug Evaluation and Research (CDER),U.S.Government Printing Office:Washington,DC,September 1997.
3. Nonsterile Semisolid Dosage Forms Scale-Up and Postapproval Changes: Chemistry,Manufacturing,and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation;Guidance for Industry; U.S. Department of Health and Human Services,Food and Drug Administration,Center for Drug Evaluation and Research (CDER),U.S. Government Printing Office: Washington, DC, May 1997.
4. Note for Guidance on Development Pharmaceutics; European Agency for the Evaluation of Medicinal Products,Human Medicines Evaluation Unit,Committee for Proprietary Medicinal Products, CPMP/QWP/155/96;London,U.K.,January 1998.
5. Note for Guidance on Modified Release Oral and Transdermal Dosage Forms:Section II (Pharmacokinetic and Clinical Evaluation);European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit,Committee for Proprietary Medicinal Products, CPMP/EWP/280/96;London,U.K., July 1999.
6. Skelly, J.; Amidon, G.; Barr, W.; Benet, L.; Carter, F.; Robinson, J.; Shah, V.; Yacobi, A. Testing and Correlation for Oral Controlled/Modified-Release Dosage Forms. Pharm. Res. 1990,7,975-982.
7. In Vitro and In Vivo Evaluation of Dosage Forms <1088>. In United States Pharmacopeia and National Formulary USP 26-NF 21;United States Pharmacopeial Convention,Inc.:Rockville,MD,2002.
8. Cardot, J-M.; Beyssac, E. In vitro/in vivo correlations: Scientific implications and standardization. Eur.J.Drug Metab.and Pharmacokinet. 1993,18,113-120.
9. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995,12, 413-420.
10. Dressman, J.; Butler, J.; Hempenstall, J.; Reppas, C. The BCS: Where do we go from here? Pharm. Tech. 2001,25 (7),68-76.
11. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System; Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER),U.S. Government Printing Office: Washington, DC, August 2000.
12. Lobenberg, R.; Amidon, G. L. Modern bioavailability and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 2000,50,3-12.
13. Martinez, M. N.; Amidon, G. L. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharmacol. 2002, 42,620-643.
14. Wilding, I. R. Evolution of the Biopharmaceutics Classification System (BCS) to oral Modified Release (MR) formulations;what do we need to consider? Eur. J. Pharm.Sci. 1999,8,157-159.
15. Abrahamsson, B.; Alpsten, M.; Bake, B.; Larsson, A.; Sjogren, J. In vitro and in vivo erosion of two different hydrophilic gel matrix tablets. Eur. J. Pharm. Biopharm. 1998,46 (1),69-75.
16. Dressman, J.; Reppas, C. In vitro-in vivo correlations for lipophilic,poorly water-soluble drugs. Eur. J. Pharm.Sci. 2000, 11 (Suppl. 2),S73-S80.
17. Dressman, J. B.; Amidon, G. L.; Reppas, C.; Shah, V. P. Dissolution testing as a prognostic tool for oral drug absorption:immediate release dosage forms. Pharm. Res. 1998,15,11-20.
18. Galia, E.; Nicolaides, E.; Hörter, D.; Löbenberg, R.; Reppas C.; Dressman J. B. Evaluation of various dissolution media for predicting in vivo performance of Class I and II drugs. Pharm.Res. 1998,15,698-705.
19. Blanquet, S.; Zeijdner, E.; Beyssac, E.; Meunier, J-P.; Denis, S.; Havenaar, R.; Alric, M. A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions. Pharm.Res. 2004,21,37-49.
20. Minekus, M.; Havenaar, R. In vitro model of an in vivo digestive tract. U.S. Patent 5,525,305,June 11,1996.
21. Minekus, M.; Marteau, P.; Havenaar, R.; Huiin’t Veld, J. H. A multi compartmental dynamic computer-controlled model simulating the stomach and small intestine. Altern.Lab.Anim. (ATLA) 1995,23,197-209.
22. Souliman, S.; Beyssac, E.; Cardot, J. M.; Denis, S.; Alric, M. Investigation of the biopharmaceutical behaviour of theophylline hydrophilic matrix tablets using USP methods and an artificial digestive system. Drug Dev. Ind. Pharm., in press.
23. Souliman, S.; Blanquet, S.; Beyssac, E.; Cardot, J-M. A level A in vitro/in vivo correlation in fasted and fed states using different methods:Applied to solid immediate release oral dosage form. Eur. J. Pharm.Sci. 2006, 27, 72-79.